Drug
Zeprumetostat
Zeprumetostat is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(25%)
Phase Distribution
Ph phase_2
2
50%
Ph phase_1
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Not yet recruiting3
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
not_yet_recruiting375%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
not_yet_recruitingphase_2
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
NCT07555470
not_yet_recruitingphase_1
Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
NCT07502768
recruitingphase_2
Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL
NCT07372352
not_yet_recruitingphase_1
EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas
NCT07339527
Clinical Trials (4)
Showing 4 of 4 trials
NCT07555470Phase 2
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
NCT07502768Phase 1
Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
NCT07372352Phase 2
Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL
NCT07339527Phase 1
EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4